PEDIATRICS Vol. 99 No. 3 March 1997, pp. 454-461 (doi:10.1542/peds.99.3.454)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rodriguez, W. J.
Right arrow Articles by Kramer, A. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rodriguez, W. J.
Right arrow Articles by Kramer, A. A.
Related Collections
Right arrow Infectious Disease & Immunity

PEDIATRICS Vol. 99 No. 3 March 1997, pp. 454-461

Respiratory Syncytial Virus (RSV) Immune Globulin Intravenous Therapy for RSV Lower Respiratory Tract Infection in Infants and Young Children at High Risk for Severe RSV Infections

Received Oct 10, 1996; accepted Dec 19, 1996.

William J. Rodriguez*, William C. GruberDagger , Robert C. Welliver§, Jessie R. Groothuisparallel , Eric A. F. Simoesparallel , H. Cody Meissner, Val G. Hemming#, Caroline B. Hall**, Martha L. LepowDagger Dagger , Angela J. Rosas§§, Christine Robertsen||, Andrew A. Kramer¶¶, and for the Respiratory Syncytial Virus Immune Globulin Study Group

From * Children's Hospital National Medical Center, Washington, DC; Dagger  Vanderbilt University Children's Hospital, Nashville, Tennessee; § Children's Hospital of Buffalo; parallel  Children's Hospital, Denver, Colorado;  New England Medical Center, Boston, Massachusetts; # Uniformed Services University of the Health Sciences, Bethesda, Maryland; ** University of Rochester Medical Center, Rochester, New York; Dagger Dagger  Albany Medical College; §§ West Virginia University School of Medicine Health Sciences Center, Morgantown; || Children's Mercy Hospital, Kansas City, Missouri; and ¶¶ MedImmune Inc, Gaithersburg, Maryland.

Objectives.  To evaluate the efficacy of high-titer intravenous respiratory syncytial virus immune globulin (RSVIG) in the treatment of children at high risk for severe RSV infection who were hospitalized with proven RSV.

Methods.  Infants and young children younger than 2 years with bronchopulmonary dysplasia, chronic lung disease, congenital heart disease, or prematurity (<32 weeks' gestational age), hospitalized with a history of lower respiratory tract infection (LRI) of less than 4 days, were enrolled in this study. Patients were randomized in a blinded fashion to receive either 1500 mg/kg RSVIG or placebo in equal volumes. They were evaluated daily for safety and respiratory scores and for RSV nasal shedding.

Results.  One hundred seven high-risk children were randomized---54 in the RSVIG group and 53 in the placebo group. Of these children, 51 in each group were considered evaluable. Children with pulmonary disease, congenital heart disease, or prematurity were equally distributed between the two treatment groups. However, two important differences were found in baseline variables between the two groups: there were more patients in the placebo group who had histories of previous LRI and there was a trend toward more severe disease at study entry in the RSVIG group. This was manifested by a higher entry respiratory score in the RSVIG group than in the placebo group (3.4 ± 0.2 vs 3.1 ± .01). A higher proportion of children in the RSVIG group (47%) than in the placebo group (28%) required intensive care at entry and mechanical ventilation at study entry (31% RSVIG-treated vs 18% placebo-treated patients). No significant difference was found between groups in the mean unadjusted duration of hospitalization (RSVIG group, 9.10 ± 1.18 days; control group, 8.17 ± 1.08 days). When the mean was adjusted for entry respiratory score, likewise, no difference was observed between each group (8.41 ± 0.97 vs 8.89 ± .99 days). The lack of efficacy observed in the study primary endpoint was observed in all diagnostic groups. No differences between the RSVIG and placebo groups were observed in the following secondary endpoints: duration of intensive care unit stay, duration of intensive care unit stay for RSV, mechanical ventilation, or supplemental oxygen. No significant differences in adverse events were reported in the RSVIG group (16 children) when compared with the control group (10 children).

Conclusion.  RSVIG treatment was safe but not efficacious in the treatment of children with bronchopulmonary dysplasia, congenital heart disease, or premature gestation who were hospitalized with RSV LRI.

Key words: respiratory syncytial virus, bronchiolitis, lower respiratory tract, infection, respiratory syncytial virus immune globulin.




This article has been cited by other articles:


Home page
 ANN INTERN MEDHome page
J. J. Treanor
Avian Influenza: Exploring All the Avenues
Ann Intern Med, October 17, 2006; 145(8): 631 - 632.
[Full Text] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
W. C. Bordley, M. Viswanathan, V. J. King, S. F. Sutton, A. M. Jackman, L. Sterling, and K. N. Lohr
Diagnosis and Testing in Bronchiolitis: A Systematic Review
Arch Pediatr Adolesc Med, February 1, 2004; 158(2): 119 - 126.
[Abstract] [Full Text] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
V. J. King, M. Viswanathan, W. C. Bordley, A. M. Jackman, S. F. Sutton, K. N. Lohr, and T. S. Carey
Pharmacologic Treatment of Bronchiolitis in Infants and Children: A Systematic Review
Arch Pediatr Adolesc Med, February 1, 2004; 158(2): 127 - 137.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. G. Ottolini, S. J. Curtis, D. D. Porter, A. Mathews, J. Y. Richardson, V. G. Hemming, and G. A. Prince
Comparison of Corticosteroids for Treatment of Respiratory Syncytial Virus Bronchiolitis and Pneumonia in Cotton Rats
Antimicrob. Agents Chemother., July 1, 2002; 46(7): 2299 - 2302.
[Abstract] [Full Text] [PDF]

Home page
 Br Med BullHome page
S. D Message and S. L Johnston
Viruses in asthma: The role of viruses in childhood respiratory infections
Br. Med. Bull., March 1, 2002; 61(1): 29 - 43.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
V. G. Hemming
Use of Intravenous Immunoglobulins for Prophylaxis or Treatment of Infectious Diseases
Clin. Vaccine Immunol., September 1, 2001; 8(5): 859 - 863.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
A. H. NUMA, G. D. WILLIAMS, and C. J. DAKIN
The Effect of Nebulized Epinephrine on Respiratory Mechanics and Gas Exchange in Bronchiolitis
Am. J. Respir. Crit. Care Med., July 1, 2001; 164(1): 86 - 91.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
S. Z. Nasr, P. J. Strouse, E. Soskolne, N. J. Maxvold, K. A. Garver, B. K. Rubin, and F. W. Moler
Efficacy of Recombinant Human Deoxyribonuclease I in the Hospital Management of Respiratory Syncytial Virus Bronchiolitis
Chest, July 1, 2001; 120(1): 203 - 208.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
M. A. Keller and E. R. Stiehm
Passive Immunity in Prevention and Treatment of Infectious Diseases
Clin. Microbiol. Rev., October 1, 2000; 13(4): 602 - 614.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
M. M. Garrison, D. A. Christakis, E. Harvey, P. Cummings, and R. L. Davis
Systemic Corticosteroids in Infant Bronchiolitis: A Meta-analysis
Pediatrics, April 1, 2000; 105(4): 44e - 44.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
A.-M. GUERGUERIAN, M. GAUTHIER, M. H. LEBEL, C. A. FARRELL, and J. LACROIX
Ribavirin in Ventilated Respiratory Syncytial Virus Bronchiolitis . A Randomized, Placebo-controlled Trial
Am. J. Respir. Crit. Care Med., September 1, 1999; 160(3): 829 - 834.
[Abstract] [Full Text]

Home page
 Clin. Microbiol. Rev.Home page
R. Weltzin and T. P. Monath
Intranasal Antibody Prophylaxis for Protection against Viral Disease
Clin. Microbiol. Rev., July 1, 1999; 12(3): 383 - 393.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
J. B. Domachowske and H. F. Rosenberg
Respiratory Syncytial Virus Infection: Immune Response, Immunopathogenesis, and Treatment
Clin. Microbiol. Rev., April 1, 1999; 12(2): 298 - 309.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
F. W. MOLER and S. E. OHMIT
Severity Of Illness Models For Respiratory Syncytial Virus-Associated Hospitalization
Am. J. Respir. Crit. Care Med., April 1, 1999; 159(4): 1234 - 1240.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
R. A. Dudas and R. A. Karron
Respiratory Syncytial Virus Vaccines
Clin. Microbiol. Rev., July 1, 1998; 11(3): 430 - 439.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
W. J. Rodriguez, W. C. Gruber, J. R. Groothuis, E. A. F. Simoes, A. J. Rosas, M. Lepow, A. K. , V. Hemming, and the RSV-IGIV Study Group
Respiratory Syncytial Virus Immune Globulin Treatment of RSV Lower Respiratory Tract Infection in Previously Healthy Children
Pediatrics, December 1, 1997; 100(6): 937 - 942.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
H. C. Meissner and J. R. Groothuis
Immunoprophylaxis and the Control of RSV Disease
Pediatrics, August 1, 1997; 100(2): 260 - 260.
[Full Text] [PDF]

Home page
 PediatricsHome page
B. Russell, C. G. Prober, and E. E. L. Wang
Reducing the Morbidity of Lower Respiratory Tract Infections Caused by Respiratory Syncytial Virus: Still No Answer
Pediatrics, March 1, 1997; 99(3): 472 - 472.
[Full Text] [PDF]